Depakote works primarily by calming overactive nerve cells in the brain through two mechanisms: blocking sodium channels that neurons use to fire electrical signals, and boosting levels of the brain’s main calming chemical, GABA. These combined effects make it useful for three FDA-approved conditions: epileptic seizures, manic episodes in bipolar disorder, and migraine prevention.
Two Mechanisms That Quiet the Brain
The active ingredient in Depakote is valproic acid (technically delivered as divalproex sodium, a compound that converts to valproic acid in the gut). Once absorbed, it works on two fronts simultaneously.
First, it blocks voltage-gated sodium channels on neurons. Neurons fire by allowing a rush of sodium ions through tiny channels in their membranes. Valproic acid obstructs those channels, which lowers the rate at which neurons can fire. Fewer rapid-fire signals means fewer of the runaway electrical cascades that cause seizures or destabilize mood.
Second, it increases GABA, the brain’s primary inhibitory neurotransmitter. GABA is essentially the brake pedal of the nervous system. Normally, an enzyme called GABA transaminase breaks GABA down after it’s done its job. Valproic acid inhibits that enzyme, so GABA sticks around longer and accumulates to higher levels. More GABA means more inhibitory signaling, which further dampens excessive neuronal activity.
Together, these two actions reduce the brain’s overall excitability. That’s why Depakote is effective across conditions that seem unrelated on the surface but share a common thread of abnormal neural firing.
How It Works for Each Condition
Seizures
Depakote is approved for complex partial seizures (which affect one area of the brain and alter awareness) and absence seizures (brief “blank stare” episodes common in children). It can be used alone or alongside other seizure medications. By suppressing abnormal electrical bursts and boosting GABA’s calming effect, it raises the threshold the brain needs to cross before a seizure can start and spread.
Bipolar Mania
During a manic episode, the brain is in a state of excessive activation. Depakote tamps that down through the same sodium channel and GABA mechanisms. In clinical trials, about 45% of patients on Depakote responded within three weeks, compared to 29% on placebo. Most studies used a 21-day treatment window, so improvement typically becomes noticeable within two to three weeks rather than days.
Migraine Prevention
Depakote is approved for reducing the frequency of migraines, not for stopping one that’s already started. The exact reason it helps with migraines is less well understood than its seizure mechanism, but it likely involves stabilizing overexcitable neurons in brain regions involved in migraine initiation. In a large placebo-controlled trial, 44 to 45% of patients on Depakote achieved at least a 50% reduction in monthly migraine attacks, compared to 21% on placebo.
How Your Body Processes It
Depakote tablets have a delayed-release coating, so the divalproex sodium doesn’t dissolve until it reaches the small intestine. There, it converts into valproic acid and gets absorbed into the bloodstream. The liver handles most of the metabolism, primarily through a process called glucuronidation and, to a lesser extent, through the CYP2C9 enzyme pathway.
Because the liver does so much of the processing, doctors typically order periodic blood work to monitor liver function. Blood tests also check the drug’s concentration to make sure it’s in the therapeutic range, since too little won’t be effective and too much increases side effect risk. These blood draws are a routine part of being on Depakote long-term.
Common Side Effects
The side effects reflect what happens when you broadly dampen neural activity and alter liver metabolism. The most frequently reported issues include nausea, drowsiness, dizziness, and tremor.
A few side effects deserve specific attention because they’re more common than people expect:
- Hair thinning: In clinical trials for epilepsy, up to 24% of patients on higher doses experienced some hair loss, compared to 13% on lower doses. In migraine prevention trials, the rate was about 7% versus 1% on placebo. Hair typically grows back after the dose is reduced or the medication is stopped.
- Weight gain: About 8 to 9% of patients in trials gained weight, compared to 2 to 4% on placebo. This is meaningful enough that some people factor it into their decision about staying on the medication.
- Low platelet counts: In one epilepsy trial using higher doses, 24% of patients developed reduced platelet levels. This is why regular blood monitoring matters. Low platelets can increase bruising and bleeding risk, and the dose may need adjustment if counts drop significantly.
Pregnancy Risk
Depakote carries a serious risk during pregnancy that goes beyond the warnings attached to most medications. A meta-analysis found that 10.7% of children exposed to valproic acid in the womb develop major birth defects, a rate substantially higher than other seizure medications. Beyond structural malformations, a large prospective study found that children exposed to valproic acid during fetal development scored 7 to 10 IQ points lower at age six compared to children exposed to other anti-seizure drugs. These risks apply throughout pregnancy, not just the first trimester. For women of childbearing age, this is typically the single most important factor in deciding whether Depakote is the right medication.